Oxford Specialist Handbook of
Pharmaceutical Medicine

Adrian Kilcoyne
Medical Director,
Sanofi Pasteur MSD Ltd,
Maidenhead, UK

Daniel O’Connor
Medical Assessor,
Medicines and Healthcare products
Regulatory Agency (MHRA),
London, UK

Phil Ambery
Director of Clinical Research,
GlaxoSmithKline R&D,
London, UK
<table>
<thead>
<tr>
<th>Section 1: Discovery of new medicines</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1 Intellectual property in discovery</td>
<td>2</td>
</tr>
<tr>
<td>1.2 Targeted drug discovery: receptor-based approaches</td>
<td>5</td>
</tr>
<tr>
<td>1.3 In vitro and in vivo testing of new compounds</td>
<td>8</td>
</tr>
<tr>
<td>1.4 Lead optimization</td>
<td>11</td>
</tr>
<tr>
<td>1.5 Natural products and herbal medicines</td>
<td>14</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Section 2: Medicines regulation</th>
<th>17</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1 General principles of medicines regulation</td>
<td>19</td>
</tr>
<tr>
<td>2.2 Medicines regulation in the UK</td>
<td>22</td>
</tr>
<tr>
<td>2.3 Medicines regulation in the EU</td>
<td>25</td>
</tr>
<tr>
<td>2.4 The European Medicines Agency and Heads of Medicines Agencies</td>
<td>31</td>
</tr>
<tr>
<td>2.5 The European Directorate for the Quality of Medicines and HealthCare, European Pharmacopoeia, and British Pharmacopoeia</td>
<td>34</td>
</tr>
<tr>
<td>2.6 The Food and Drug Administration</td>
<td>37</td>
</tr>
<tr>
<td>2.7 Health Canada</td>
<td>40</td>
</tr>
<tr>
<td>2.8 Medsafe and the Therapeutic Goods Administration</td>
<td>42</td>
</tr>
<tr>
<td>2.9 Medicines regulation in Japan</td>
<td>45</td>
</tr>
<tr>
<td>2.10 Medicines regulation in China</td>
<td>49</td>
</tr>
<tr>
<td>2.11 Medical device regulation</td>
<td>52</td>
</tr>
<tr>
<td>2.12 Clinical trials regulation</td>
<td>55</td>
</tr>
<tr>
<td>2.13 Good clinical practice</td>
<td>58</td>
</tr>
<tr>
<td>2.14 Good laboratory practice and good clinical laboratory practice</td>
<td>61</td>
</tr>
<tr>
<td>2.15 Good manufacturing practice</td>
<td>64</td>
</tr>
<tr>
<td>2.16 The Ethics Committee (EU)</td>
<td>67</td>
</tr>
<tr>
<td>2.17 The Institutional Review Board (US)</td>
<td>71</td>
</tr>
</tbody>
</table>
2.18 Marketing authorization applications and updating and maintaining licences 74
2.19 The International Conference on Harmonisation 77
2.20 Common technical document 80
2.21 Medicinal product information in the European Union 84
2.22 Summary of product characteristics 87
2.23 Orphan drugs 90
2.24 Paediatric investigational plans 93
2.25 Regulatory requirements for pharmacovigilance 95
2.26 Overview of reporting of adverse drug reactions 98
2.27 Non-prescription drugs 101
2.28 Provision of unlicensed medicines 104
2.29 Reclassification of medicines 107
2.30 Parallel imports 111

Section 3: Clinical pharmacology 113

3.1 Absorption, distribution, metabolism, and excretion 115
3.2 Volume of distribution, clearance, half-life 119
3.3 Pre-clinical aspects of pharmacokinetics 123
3.4 Non-clinical data 126
3.5 Clinical aspects of pharmacokinetics 129
3.6 Dose–response relationship 132
3.7 Proof of concept studies 136
3.8 Reproductive toxicity studies 138
3.9 Immunotoxicity testing 142
3.10 Carcinogenicity 146
3.11 Genotoxicity testing 149
3.12 Local tolerance 153
3.13 Acute toxicity 156
3.14 Studies: objectives, design, conduct, and analysis 158
3.15 Populations for exploratory studies and planning of exploratory studies 162
3.16 Pharmacodynamic endpoints 165
3.17 Bioavailability and bioequivalence 168
3.18 Evaluation of safety and tolerability 171
3.19 Hypersensitivity reactions 174
3.20 Drug–drug interactions 177
3.21 Ethics in research: basic principles, Declaration of Helsinki, and Council for International Organizations of Medical Sciences 181
3.22 Disease models 185
3.23 Biomarkers 188
3.24 Pharmacogenetics 191
3.25 Population pharmacokinetics 193
3.26 Small molecules and biologicals: safety and pharmacology requirements 195

Section 4: Clinical development

4.1 Requirements for licensing a new medicinal product 200
4.2 Regulatory guidance 203
4.3 General principles of clinical trial protocols 206
4.4 Clinical study design 209
4.5 Adaptive trial designs 213
4.6 Informed consent 215
4.7 Data protection 218
4.8 Indemnity and compensation 221
4.9 Investigator’s brochure 224
4.10 Organization of project teams/project planning 227
4.11 Contractual arrangements with research sites and contract research organizations 230
4.12 Case report form 233
4.13 Budgeting and cost control 236
4.14 Expanded access programmes 239
4.15 Study master file preparation 242
4.16 Target product profile 247

Section 5: Statistics and data management

5.1 Determining the sample size in a clinical trial 252
5.2 Sensitivity and specificity 255
5.3 Significance testing 258
5.4 Type I and Type II error 261
5.5 Confidence intervals 264
5.6 Minimizing bias 268
5.7 Paired and unpaired t-tests 271
5.8 Parametric and non-parametric tests 274
5.9 Patient reported outcomes 277
5.10 Health-related quality of life 280
5.11 Clinical interpretation of trial results 283
5.12 Clinical study report 289
5.13 Issues with making trial results available 292
5.14 Interim analysis 295
5.15 Data management 298
5.16 Within trial data management 301

Section 6: Drug safety and pharmacovigilance 305
6.1 Pharmacovigilance 306
6.2 Key pharmacovigilance regulations in the EU 309
6.3 Good pharmacovigilance practices 312
6.4 Periodic safety update reports 315
6.5 Benefit–risk assessment 318
6.6 Pharmacoepidemiological safety data 322
6.7 Product suspension and withdrawal and defective medicines 325
6.8 Safety signal 328
6.9 Spontaneous reporting 331
6.10 Post-authorization safety studies 334
6.11 Dear Healthcare Professional communication 337
6.12 Issues and crisis management 339
6.13 Adverse events in clinical trials 342
6.14 Risk management 346

Section 7: Healthcare marketplace 349
7.1 Marketing medicines: the drug lifecycle 351
7.2 The Foreign Corrupt Practices Act and UK Bribery Act 355
7.3 Product lifecycle management 359
7.4 Ethical marketing of medicines 362
7.5 World Health Organization ethical criteria for medicinal drug promotion 365
7.6 Co-marketing and co-promotion 368
7.7 In-licensing 370
7.8 The Association of British Pharmaceutical Industries 373
7.9 The Association of British Pharmaceutical Industries Code of Practice 376
7.10 Pharmaceutical Research and Manufacturers of America 379
7.11 The International Federation of Pharmaceutical Manufacturers & Associations Code of Practice 382
7.12 The European Federation of Pharmaceutical Industries and Associations 384
7.13 Medicines Australia 387
7.14 National Institute for Health and Clinical Excellence 390
7.15 The Scottish Intercollegiate Guidelines Network 393
7.16 The Institute for Quality and Efficiency in Health Care 396
7.17 Health economics 399
7.18 Quality-adjusted life years 402
7.19 Pharmacoepidemiology 405
7.20 Branded generics 408
7.21 Intellectual property 411
7.22 Product liability and compensation 414

Section 8: Therapeutics

8.1 Medicines for children 418
8.2 Medicines in pregnancy 421
8.3 Medicines in the elderly 425
8.4 Medicines for patients with hepatic impairment 429
8.5 Medicines for patients with renal impairment 433
8.6 Principles of benefit–risk 436
8.7 Therapeutic drug monitoring 439

Index 441